DMK Pharmaceuticals Corporation (0A4X.L)

0.0600 +0.0267 (+80.18%) At close: 06:57PM BST

DMK Pharmaceuticals Corporation

11682 El Camino Real
Suite 300
San Diego, CA 92130
United States
858 997 2400
https://www.dmkpharmaceuticals.com

Sector(s): 
Industry: 
Full-time employees: 11

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Seth Abraham Cohen	Chief Financial Officer	N/A	N/A	1963
Mr. John W. Dorbin Jr.	General Counsel Corporate Secretary	N/A	N/A	1971
Mr. Eddie Wabern Glover	Chief Executive Officer of US Compounding Inc	N/A	N/A	1950

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California. On February 2, 2024, DMK Pharmaceuticals Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Corporate governance

DMK Pharmaceuticals Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.